Roche’s enicepatide shows dose-dependent blood sugar and weight loss in Phase 2 diabetes trial

Roche reported that its injectable GLP-1/GIP dual agonist enicepatide, acquired through the Carmot Therapeutics purchase, achieved reductions in blood glucose and body weight in a Phase 2 study of overweight or obese patients with type-2 diabetes.

The trial, identified as CT-388-104, evaluated multiple dose levels over 48 weeks. Results showed dose-dependent improvements, with the highest dose lowering HbA1c by about 2.65% on average.

Participants who entered the study with poor glycemic control saw even larger reductions, roughly 4% in HbA1c, according to Roche’s release. The company described the glycemic control as best-in-disease.

Roche highlighted the readout as part of a broader set of upcoming milestones in its metabolic pipeline, which also includes assets from partner Zealand Pharma. The data adds momentum to the company’s strategy in the diabetes market.